Table 2.
Most significant KEGG pathways with altered expression in terms of disease
| Name of pathway | Count | p-value | Fold enrichment | FDR |
|---|---|---|---|---|
| CCGs | ||||
| Oxidative phosphorylation | 22 | 3.18E−19 | 12.11 | 2.62E−14 |
| *Parkinson’s disease | 21 | 2.63E−17 | 10.82 | 1.81E−12 |
| Alzheimer’s disease | 22 | 4.60E−17 | 9.58 | 3.75E−12 |
| *Non-alcoholic fatty liver disease (NAFLD) | 21 | 1.12E−14 | 8.00 | 6.41E−10 |
| Huntington’s disease | 19 | 2.72E−14 | 9.21 | 1.05E−09 |
| Metabolic pathways | 41 | 7.24E−12 | 2.52 | 3.04E−06 |
| ICGs | ||||
| Vitamin digestion and absorption | 8 | 1.22E−7 | 18.53 | 1.52E−04 |
| Fat digestion and absorption | 41 | 3.57E−4 | 1.71 | 0.4450 |
| Protein digestion and absorption | 6 | 8.80E−4 | 7.84 | 1.0931 |
| Metabolic pathways | 8 | 1.63E−3 | 4.63 | 1.9248 |
| Chemical carcinogenesis | 7 | 4.53E−3 | 4.46 | 5.4888 |
* Indicates the associations with CD were previously reported. Count: number of genes; p-value: modified Fisher Exact p-value, EASE Score, the smaller, the more enriched; Fold Enrichment: − log (p-value); CCGs: colonic CD genes; ICGs: terminal-ileal CD genes